Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders

Rhea-AI Summary

Aeterna Zentaris Inc. (NASDAQ: AEZS) held its Annual General Meeting on May 5, 2021, where new directors were elected. Peter Edwards received 85.74% support, Carolyn Egbert 87.65%, Gilles Gagnon 85.52%, Klaus Paulini 92.08%, and Dennis Turpin was welcomed to the board. Ernst & Young LLP was appointed as the independent auditor. The company remains an 'Eligible Interlisted Issuer,' exempt from certain Canadian requirements regarding its long-term incentive plan. Details are available on SEDAR and EDGAR.

Positive

• Peter Edwards elected with 85.74% support.
• Ernst & Young appointed as independent auditor.
• Dennis Turpin joins the board of directors.

Negative

• None.

CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the results from its Annual General Meeting (“AGM”) held today, May 5, 2021.

The individuals noted below were elected as directors of the Company. The report on voting results provided by the Company’s transfer agent indicated the following:

Name of Nominee	Votes For	%		Votes Withheld	%
Peter Edwards	7,372,226	85.74	%	1,226,203	14.26	%
Carolyn Egbert	7,536,307	87.65	%	1,062,122	12.35	%
Gilles Gagnon	7,353,055	85.52	%	1,245,374	14.48	%
Klaus Paulini	7,917,497	92.08	%	680,932	7.92	%
Dennis Turpin	7,525,819	87.53	%	1,072,610	12.47	%

The Company would like to welcome Dennis Turpin to the board of directors.

Ernst & Young LLP was also appointed as the Company’s independent auditor at the AGM.

The Company is an “Eligible Interlisted Issuer” as such term is defined in the TSX Company Manual. As an Eligible Interlisted Issuer, the Company has relied on an exemption pursuant to Section 602.1 of the TSX Company Manual from Section 613 of the TSX Company Manual, the effect of which is that, subject to the satisfaction of certain conditions prescribed by the Toronto Stock Exchange, the Company will not have to comply with certain Canadian requirements in connection with the Company’s long-term incentive plan. As a result, shareholders were not asked to approve the unallocated entitlements under the Company’s long-term incentive plan at the AGM.

For full voting details please see the report of voting results of Aeterna as filed on SEDAR at www.sedar.com and EDGAR at www.sec.gov.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company’s lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD) in collaboration with Novo Nordisk.

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pipeline to address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), primary hypoparathyroidism and an undisclosed neurodegenerative disease. Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2, the virus that causes COVID-19.

For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: aezs@jtcir.com

FAQ

What were the results of the Aeterna Zentaris AGM held on May 5, 2021?

At the AGM, Aeterna Zentaris elected Peter Edwards, Carolyn Egbert, Gilles Gagnon, Klaus Paulini, and welcomed Dennis Turpin to the board, with Ernst & Young appointed as the independent auditor.

Who were elected as directors at Aeterna Zentaris AGM?

The elected directors were Peter Edwards, Carolyn Egbert, Gilles Gagnon, Klaus Paulini, and Dennis Turpin.

What percentage of votes did Klaus Paulini receive at the AGM?

Klaus Paulini received 92.08% of the votes at the Aeterna Zentaris AGM.

What is the significance of Aeterna Zentaris being an 'Eligible Interlisted Issuer'?

Being an 'Eligible Interlisted Issuer' allows Aeterna Zentaris to avoid certain Canadian compliance requirements regarding its long-term incentive plan.